View Item 

Show simple item record

Chronic inflammatory demyelinating polyradiculoneuropathy—Diagnostic pitfalls and treatment approach
dc.contributor.authorStino, Amro M.
dc.contributor.authorNaddaf, Elie
dc.contributor.authorDyck, Peter J.
dc.contributor.authorDyck, P. James B.
dc.date.accessioned2021-02-04T21:49:03Z
dc.date.available2022-03-04 16:49:00en
dc.date.available2021-02-04T21:49:03Z
dc.date.issued2021-02
dc.identifier.citationStino, Amro M.; Naddaf, Elie; Dyck, Peter J.; Dyck, P. James B. (2021). "Chronic inflammatory demyelinating polyradiculoneuropathy—Diagnostic pitfalls and treatment approach." Muscle & Nerve 63(2): 157-169.
dc.identifier.issn0148-639X
dc.identifier.issn1097-4598
dc.identifier.urihttps://hdl.handle.net/2027.42/166169
dc.description.abstractChronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is characterized by progressive weakness and sensory loss, often affecting patientsʼ ability to walk and perform activities of daily living independently. With the lack of a diagnostic biomarker, the diagnosis relies on clinical suspicion, clinical findings, and the demonstration of demyelinating changes on electrodiagnostic (EDx) testing and nerve pathology. As a result, patients can often be misdiagnosed with CIDP and unnecessarily treated with immunotherapy. Interpreting the EDx testing and cerebrospinal fluid findings in light of the clinical phenotype, recognizing atypical forms of CIDP, and screening for CIDP mimickers are the mainstays of the approach to patients suspected of having CIDP, and are detailed in this review. We also review the currently available treatment options, including intravenous immunoglobulin (IVIg), corticosteroids (CCS), and plasma exchange (PE), and discuss how to approach treatment‐refractory cases. Finally, we emphasize the need to adopt objective outcome measures to monitor treatment response.
dc.publisherJohn Wiley & Sons, Inc.
dc.subject.otherCIDP, diagnosis, IVIg, plasma exchange, steroids, treatment
dc.titleChronic inflammatory demyelinating polyradiculoneuropathy—Diagnostic pitfalls and treatment approach
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelNeurosciences
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/166169/1/mus27046.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/166169/2/mus27046_am.pdf
dc.identifier.doi10.1002/mus.27046
dc.identifier.doihttps://dx.doi.org/10.7302/92
dc.identifier.sourceMuscle & Nerve
dc.identifier.citedreferenceOwen HG, Brecher ME. Atypical reactions associated with use of angiotensin‐converting enzyme inhibitors and apheresis. Transfusion. 1994; 34: 891 ‐ 894.
dc.identifier.citedreferenceBrannagan TH, Pradhan A, Heiman‐Patterson T, et al. High‐dose cyclophosphamide without stem‐cell rescue for refractory CIDP. Neurology. 2002; 58: 1856 ‐ 1858.
dc.identifier.citedreferenceGladstone DE, Prestrud AA, Brannagan TH. High‐dose cyclophosphamide results in long‐term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst. 2005; 10: 11 ‐ 16.
dc.identifier.citedreferenceMahdi‐Rogers M, Brassington R, Gunn AA, van Doorn PA, Hughes RA. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2017; 5: CD003280.
dc.identifier.citedreferenceDyck PJ, O’Brien P, Swanson C, Low P, Daube J. Combined azathioprine and prednisone in chronic inflammatory‐demyelinating polyneuropathy. Neurology. 1985; 35: 1173 ‐ 1176.
dc.identifier.citedreferenceHughes R, Dalakas MC, Merkies I, et al. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double‐blind, multicentre, randomised controlled trial. Lancet Neurol. 2018; 17: 689 ‐ 698.
dc.identifier.citedreferenceRMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol. 2009; 8: 158 ‐ 164.
dc.identifier.citedreferenceAl‐Zuhairy A, Sindrup SH, Andersen H, Jakobsen J. A population‐based study of long‐term outcome in treated chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2020; 61: 316 ‐ 324.
dc.identifier.citedreferenceBunschoten C, Eftimov F, van der Pol WL, Jacobs BC. International chronic inflammatory demyelinating polyneuropathy outcome study (ICOS): protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome. J Peripher Nerv Syst. 2019; 24: 34 ‐ 38.
dc.identifier.citedreferenceDyck PJ, Sherman WR, Hallcher LM, et al. Human diabetic endoneurial sorbitol, fructose, and myo‐inositol related to sural nerve morphometry. Ann Neurol. 1980; 8: 590 ‐ 596.
dc.identifier.citedreferenceDyck PJ, Taylor BV, Davies JL, et al. Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. Muscle Nerve. 2015; 52: 488 ‐ 497.
dc.identifier.citedreferenceDyck PJB, González‐Duarte A, Obici L, et al. Development of measures of polyneuropathy impairment in hATTR amyloidosis: from NIS to mNIS + 7. J Neurol Sci. 2019; 405: 116424.
dc.identifier.citedreferenceVanhoutte EK, Faber CG, Merkies IS. PeriNomS study group. 196th ENMC International Workshop: Outcome Measures in Inflammatory Peripheral Neuropathies 8‐10 February 2013, Naarden, The Netherlands. Neuromuscul Disord. 2013; 23: 924 ‐ 933.
dc.identifier.citedreferenceAllen JA, Merkies ISJ, Lewis RA. Monitoring clinical course and treatment response in chronic inflammatory demyelinating polyneuropathy during routine care: a review of clinical and laboratory assessment measures. JAMA Neurol. (to be published). 2020; doi:10.1001/jamaneurol.2020.0781.
dc.identifier.citedreferenceDraak TH, Gorson KC, Vanhoutte EK, et al. Correlation of the patientʼs reported outcome Inflammatory‐RODS with an objective metric in immune‐mediated neuropathies. Eur J Neurol. 2016; 23: 1248 ‐ 1253.
dc.identifier.citedreferenceFokkink W, Koch B, Ramakers C, van Doorn PA, van Gelder T, Jacobs BC. Pharmacokinetics and pharmacodynamics of intravenous immunoglobulin G maintenance therapy in chronic immune‐mediated neuropathies. Clin Pharmacol Ther. 2017; 102: 709 ‐ 716.
dc.identifier.citedreferencevan Nes SI, Vanhoutte EK, van Doorn PA, et al. Rasch‐built Overall Disability Scale (R‐ODS) for immune‐mediated peripheral neuropathies. Neurology. 2011; 76: 337 ‐ 345.
dc.identifier.citedreferenceRajabally YA, Fatehi F. Outcome measures for chronic inflammatory demyelinating polyneuropathy in research: relevance and applicability to clinical practice. Neurodegener Dis Manag. 2019; 9: 259 ‐ 266.
dc.identifier.citedreferenceMerkies IS, van Nes SI, Hanna K, Hughes RA, Deng C. Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance. J Neurol Neurosurg Psychiatry. 2010; 81: 1194 ‐ 1199.
dc.identifier.citedreferenceJaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989; 10: 407 ‐ 415.
dc.identifier.citedreferenceDyck PJB, Tracy JA. History, diagnosis, and management of chronic inflammatory demyelinating polyradiculoneuropathy. Mayo Clin Proc. 2018; 93: 777 ‐ 793.
dc.identifier.citedreferenceDyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc. 1975; 50: 621 ‐ 637.
dc.identifier.citedreferenceLaughlin RS, Dyck PJ, Melton LJ, Leibson C, Ransom J, Dyck PJB. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology. 2009; 73: 39 ‐ 45.
dc.identifier.citedreferenceRajabally YA, Simpson BS, Beri S, Bankart J, Gosalakkal JA. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve. 2009; 39: 432 ‐ 438.
dc.identifier.citedreferenceBroers MC, Bunschoten C, Nieboer D, Lingsma HF, Jacobs BC. Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta‐analysis. Neuroepidemiology. 2019; 52: 161 ‐ 172.
dc.identifier.citedreferenceTracy JA, Dyck PJ, Klein CJ, Engelstad JK, Meyer JE, Dyck PJB. Onion‐bulb patterns predict acquired or inherited demyelinating polyneuropathy. Muscle Nerve. 2019; 59: 665 ‐ 670.
dc.identifier.citedreferenceDalakas MC. Pathogenesis of immune‐mediated neuropathies. Biochim Biophys Acta. 1852; 2015: 658 ‐ 666.
dc.identifier.citedreferenceBunschoten C, Jacobs BC, Van den Bergh PYK, Cornblath DR, van Doorn PA. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol. 2019; 18: 784 ‐ 794.
dc.identifier.citedreferenceVan den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revision. Eur J Neurol. 2010; 17: 356 ‐ 363.
dc.identifier.citedreferenceAllen JA, Lewis RA. CIDP diagnostic pitfalls and perception of treatment benefit. Neurology. 2015; 85: 498 ‐ 504.
dc.identifier.citedreferenceAllen JA, Ney J, Lewis RA. Electrodiagnostic errors contribute to chronic inflammatory demyelinating polyneuropathy misdiagnosis. Muscle Nerve. 2018; 57: 542 ‐ 549.
dc.identifier.citedreferenceLewis RA. Chronic inflammatory demyelinating polyneuropathy. Curr Opin Neurol. 2017; 30: 508 ‐ 512.
dc.identifier.citedreferenceBunschoten C, Blomkwist‐Markens PH, Horemans A, van Doorn PA, Jacobs BC. Clinical factors, diagnostic delay, and residual deficits in chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2019; 24: 253 ‐ 259.
dc.identifier.citedreferenceSinnreich M, Klein CJ, Daube JR, Engelstad J, Spinner RJ, Dyck PJ. Chronic immune sensory polyradiculopathy: a possibly treatable sensory ataxia. Neurology. 2004; 63: 1662 ‐ 1669.
dc.identifier.citedreferenceDimachkie MM, Barohn RJ, Katz J. Multifocal motor neuropathy, multifocal acquired demyelinating sensory and motor neuropathy, and other chronic acquired demyelinating polyneuropathy variants. Neurol Clin. 2013; 31: 533 ‐ 555.
dc.identifier.citedreferenceFigueroa JJ, Dyck PJB, Laughlin RS, et al. Autonomic dysfunction in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology. 2012; 78: 702 ‐ 708.
dc.identifier.citedreferenceBarohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol. 1989; 46: 878 ‐ 884.
dc.identifier.citedreferenceKalita J, Misra UK, Yadav RK. A comparative study of chronic inflammatory demyelinating polyradiculoneuropathy with and without diabetes mellitus. Eur J Neurol. 2007; 14: 638 ‐ 643.
dc.identifier.citedreferenceBreiner A, Bourque PR, Allen JA. Updated cerebrospinal fluid total protein reference values improve chronic inflammatory demyelinating polyneuropathy diagnosis. Muscle Nerve. 2019; 60: 180 ‐ 183.
dc.identifier.citedreferenceAbe Y, Terashima H, Hoshino H, et al. Characteristic MRI features of chronic inflammatory demyelinating polyradiculoneuropathy. Brain Dev. 2015; 37: 894 ‐ 896.
dc.identifier.citedreferenceGoedee HS, van der Pol WL, van Asseldonk JH, et al. Diagnostic value of sonography in treatment‐naive chronic inflammatory neuropathies. Neurology. 2017; 88: 143 ‐ 151.
dc.identifier.citedreferenceDi Pasquale A, Morino S, Loreti S, Bucci E, Vanacore N, Antonini G. Peripheral nerve ultrasound changes in CIDP and correlations with nerve conduction velocity. Neurology. 2015; 84: 803 ‐ 809.
dc.identifier.citedreferenceSimmons Z, Wald JJ, Albers JW. Chronic inflammatory demyelinating polyradiculoneuropathy in children: II. Long‐term follow‐up, with comparison to adults. Muscle Nerve. 1997; 20: 1569 ‐ 1575.
dc.identifier.citedreferenceRuts L, Drenthen J, Jacobs BC, van Doorn PA. Dutch GBS Study Group. Distinguishing acute‐onset CIDP from fluctuating Guillain‐Barré syndrome: a prospective study. Neurology. 2010; 74: 1680 ‐ 1686.
dc.identifier.citedreferenceOh SJ, Kurokawa K, de Almeida DF, Ryan HF, Claussen GC. Subacute inflammatory demyelinating polyneuropathy. Neurology. 2003; 61: 1507 ‐ 1512.
dc.identifier.citedreferenceHughes RA. The spectrum of acquired demyelinating polyradiculoneuropathy. Acta Neurol Belg. 1994; 94: 128 ‐ 132.
dc.identifier.citedreferenceVural A, Doppler K, Meinl E. Autoantibodies against the node of Ranvier in seropositive chronic inflammatory demyelinating polyneuropathy: diagnostic, pathogenic, and therapeutic relevance. Front Immunol. 2018; 9: 1029.
dc.identifier.citedreferenceQuerol L, Illa I. Paranodal and other autoantibodies in chronic inflammatory neuropathies. Curr Opin Neurol. 2015; 28: 474 ‐ 479.
dc.identifier.citedreferenceAllen JA, Berger M, Querol L, Kuitwaard K, Hadden RD. Individualized immunoglobulin therapy in chronic immune‐mediated peripheral neuropathies. J Peripher Nerv Syst. 2018; 23: 78 ‐ 87.
dc.identifier.citedreferenceOh SJ, Joy JL, Kuruoglu R. "Chronic sensory demyelinating neuropathy": chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry. 1992; 55: 677 ‐ 680.
dc.identifier.citedreferenceTaylor BV, Dyck PJB, Engelstad J, Gruener G, Grant I, Dyck PJ. Multifocal motor neuropathy: pathologic alterations at the site of conduction block. J Neuropathol Exp Neurol. 2004; 63: 129 ‐ 137.
dc.identifier.citedreferenceLewis RA, Sumner AJ. The electrodiagnostic distinctions between chronic familial and acquired demyelinative neuropathies. Neurology. 1982; 32: 592 ‐ 596.
dc.identifier.citedreferenceKatz JS, Saperstein DS, Gronseth G, Amato AA, Barohn RJ. Distal acquired demyelinating symmetric neuropathy. Neurology. 2000; 54: 615 ‐ 620.
dc.identifier.citedreferenceMauermann ML. Paraproteinemic neuropathies. Continuum (Minneap Minn). 2014; 20: 1307 ‐ 1322.
dc.identifier.citedreferenceGosselin S, Kyle RA, Dyck PJ. Neuropathy associated with monoclonal gammopathies of undetermined significance. Ann Neurol. 1991; 30: 54 ‐ 61.
dc.identifier.citedreferenceDispenzieri A. How I treat POEMS syndrome. Blood. 2012; 119: 5650 ‐ 5658.
dc.identifier.citedreferenceNaddaf E, Dispenzieri A, Mandrekar J, Mauermann ML. Thrombocytosis distinguishes POEMS syndrome from chronic inflammatory demyelinating polyneuropathy. Muscle Nerve. 2015; 52: 658 ‐ 659.
dc.identifier.citedreferenceMauermann ML, Sorenson EJ, Dispenzieri A, Mandrekar J, Suarez GA, Dyck PJB. Uniform demyelination and more severe axonal loss distinguish POEMS syndrome from CIDP. J Neurol Neurosurg Psychiatry. 2012; 83: 480 ‐ 486.
dc.identifier.citedreferencePiccione EA, Engelstad J, Dyck PJ, Mauermann ML, Dispenzieri A, Dyck PJB. Nerve pathologic features differentiate POEMS syndrome from CIDP. Acta Neuropathol Commun. 2016; 4: 116.
dc.identifier.citedreferenceEftimov F, Vermeulen M, van Doorn PA, Brusse E, van Schaik IN, PREDICT. Long‐term remission of CIDP after pulsed dexamethasone or short‐term prednisolone treatment. Neurology. 2012; 78: 1079 ‐ 1084.
dc.identifier.citedreferenceAdams D, Ando Y, Beirão JM, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. (to be published). 2020; doi:10.1007/s00415-019-09688-0.
dc.identifier.citedreferenceKelly JJ, Karcher DS. Lymphoma and peripheral neuropathy: a clinical review. Muscle Nerve. 2005; 31: 301 ‐ 313.
dc.identifier.citedreferenceDyck PJB, Norell JE, Dyck PJ. Non‐diabetic lumbosacral radiculoplexus neuropathy: natural history, outcome and comparison with the diabetic variety. Brain. 2001; 124: 1197 ‐ 1207.
dc.identifier.citedreferenceGarces‐Sanchez M, Laughlin RS, Dyck PJ, Engelstad JK, Norell JE, Dyck PJB. Painless diabetic motor neuropathy: a variant of diabetic lumbosacral radiculoplexus neuropathy? Ann Neurol. 2011; 69: 1043 ‐ 1054.
dc.identifier.citedreferenceDyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994; 36: 838 ‐ 845.
dc.identifier.citedreferenceHughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate‐chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo‐controlled trial. Lancet Neurol. 2008; 7: 136 ‐ 144.
dc.identifier.citedreferenceNobile‐Orazio E, Cocito D, Jann S, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol. 2012; 11: 493 ‐ 502.
dc.identifier.citedreferenceEftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2013; 12: CD001797.
dc.identifier.citedreferenceLabasque M, Hivert B, Nogales‐Gadea G, Querol L, Illa I, Faivre‐Sarrailh C. Specific contactin N‐glycans are implicated in neurofascin binding and autoimmune targeting in peripheral neuropathies. J Biol Chem. 2014; 289: 7907 ‐ 7918.
dc.identifier.citedreferenceQuerol L, Nogales‐Gadea G, Rojas‐Garcia R, et al. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology. 2014; 82: 879 ‐ 886.
dc.identifier.citedreferenceLunn MP, Ellis L, Hadden RD, Rajabally YA, Winer JB, Reilly MM. A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies. J Peripher Nerv Syst. 2016; 21: 33 ‐ 37.
dc.identifier.citedreferenceKuitwaard K, van Doorn PA, Vermeulen M, et al. Serum IgG levels in IV immunoglobulin treated chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 2013; 84: 859 ‐ 861.
dc.identifier.citedreferencevan Doorn PA, Kuitwaard K, Jacobs BC. Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDP. J Peripher Nerv Syst. 2011; 16 ( Suppl 1 ): 38 ‐ 40.
dc.identifier.citedreferenceRajabally YA, Wong SL, Kearney DA. Immunoglobulin G level variations in treated chronic inflammatory demyelinating polyneuropathy: clues for future treatment regimens? J Neurol. 2013; 260: 2052 ‐ 2056.
dc.identifier.citedreferenceRajabally YA, Afzal S. Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy. J Neurol. 2019; 266: 461 ‐ 467.
dc.identifier.citedreferenceCornblath DR, Hartung HP, Katzberg HD, Merkies ISJ, van Doorn PA. A randomised, multi‐centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): study design and protocol. J Peripher Nerv Syst. 2018; 23: 108 ‐ 114.
dc.identifier.citedreferenceKuitwaard K, Fokkink WR, Brusse E, et al. Protocol of a dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (DRIP study). J Peripher Nerv Syst. 2018; 23: 5 ‐ 10.
dc.identifier.citedreferenceBonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am. 2008; 28: 803 ‐ 819. ix.
dc.identifier.citedreferenceBerger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol. 2011; 139: 133 ‐ 141.
dc.identifier.citedreferenceGuo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Front Immunol. 2018; 9: 1299.
dc.identifier.citedreferenceKapoor M, Spillane J, Englezou C, et al. Thromboembolic risk with IVIg: incidence and risk factors in patients with inflammatory neuropathy. Neurology. 2020; 94: e635 ‐ e638.
dc.identifier.citedreferencevan Schaik IN, Bril V, van Geloven N, et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurol. 2018; 17: 35 ‐ 46.
dc.identifier.citedreferenceWasserman RL. Common infusion‐related reactions to subcutaneous immunoglobulin therapy: managing patient expectations. Patient Prefer Adherence. 2008; 2: 163 ‐ 166.
dc.identifier.citedreferenceNaddaf E, Murad MH, Dyck PJB. Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies. Muscle Nerve. 2017; 55: 775 ‐ 776.
dc.identifier.citedreferenceDyck PJ, PC OB, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol. 1982; 11: 136 ‐ 141.
dc.identifier.citedreferenceHughes R, Bensa S, Willison H, Van den Bergh P, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001; 50: 195 ‐ 201.
dc.identifier.citedreferencevan Schaik IN, Eftimov F, van Doorn PA, et al. Pulsed high‐dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double‐blind, randomised, controlled trial. Lancet Neurol. 2010; 9: 245 ‐ 253.
dc.identifier.citedreferenceLopate G, Pestronk A, Al‐Lozi M. Treatment of chronic inflammatory demyelinating polyneuropathy with high‐dose intermittent intravenous methylprednisolone. Arch Neurol. 2005; 62: 249 ‐ 254.
dc.identifier.citedreferenceRabin M, Mutlu G, Stojkovic T, Maisonobe T, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: search for factors associated with treatment dependence or successful withdrawal. J Neurol Neurosurg Psychiatry. 2014; 85: 901 ‐ 906.
dc.identifier.citedreferenceAdrichem ME, Bus SR, Wieske L, et al. Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study. Eur J Neurol. 2020; 27: 506 ‐ 513.
dc.identifier.citedreferenceCartwright SL, Cartwright MS. Health maintenance for adults with neuromuscular diseases on immunosuppression. Muscle Nerve. 2019; 59: 397 ‐ 403.
dc.identifier.citedreferenceDyck PJ, Daube J, OʼBrien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med. 1986; 314: 461 ‐ 465.
dc.identifier.citedreferenceHahn AF, Bolton CF, Pillay N, et al. Plasma‐exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double‐blind, sham‐controlled, cross‐over study. Brain. 1996; 119: 1055 ‐ 1066.
dc.identifier.citedreferenceQuerol L, Rojas‐García R, Diaz‐Manera J, et al. Rituximab in treatment‐resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm. 2015; 2: e149.
dc.identifier.citedreferenceDelmont E, Brodovitch A, Kouton L, et al. Antibodies against the node of Ranvier: a real‐life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera. J Neurol. (to be published). DOI:10.1007/s00415-020-10041-z.
dc.identifier.citedreferenceRoux T, Debs R, Maisonobe T, et al. Rituximab in chronic inflammatory demyelinating polyradiculoneuropathy with associated diseases. J Peripher Nerv Syst. 2018; 23: 235 ‐ 240.
dc.identifier.citedreferenceGood JL, Chehrenama M, Mayer RF, Koski CL. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology. 1998; 51: 1735 ‐ 1738.
dc.working.doi10.7302/92en
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
mus27046.pdf
Size:
2.438MB
Format:
PDF
View/Open
Name:
mus27046_am.pdf
Size:
12.25MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.